EX-10.5



 Exhibit 10.5 





 
 December 17, 2012 

Michael Grey 
 7848 Sendero Angelica 

San Diego, CA 92127 
  

	Re:	Employment Terms 

 Dear Mike: 

This letter (the “Agreement”) is to confirm our understanding with respect to the terms of your continued employment as Chief Executive Officer of
Lumena Pharmaceuticals, Inc. (the “Company”) and replaces and supersedes in full that certain letter agreement between you and the Company dated February 7, 2011 (the “Prior Offer Letter”). 

You will report to the Board of Directors of the Company (the “Board”) and will work at our headquarters located in San Diego, California. You will
devote substantially all of your working time and efforts to the business and affairs of the Company; provided, however, that you may continue the affiliations listed on EXHIBIT A attached hereto and such other outside
professional affiliations as are approved from time to time by the Board. Subject to the terms hereof, the Company may change your position, duties and work location from time to time in its discretion. 

You will be paid a base salary of $300,000 per year (the “Base Salary”), effective retroactively to June 19, 2012. Your Base Salary will be
paid bi-weekly and will be subject to payroll deductions and all required withholdings. Your Base Salary will be pro-rated for any partial year of employment on the basis of a 365-day fiscal year. 

In addition, you will be eligible for an annual discretionary bonus of up to 35% of your Base Salary as then in effect based on achievement of the specific
performance goals for each fiscal year to be established by the Board (the “Performance Goals”) (the bonus, “Discretionary Annual Bonus”). The specific amount of your Discretionary Annual Bonus, if any, shall be determined by the
Board based upon its evaluation of the Performance Goals and shall be subject to your continued employment through the date such bonus is paid. Your Discretionary Annual Bonus, if any, will be pro-rated for any partial year of employment on the
basis of a 365-day fiscal year. In all events, any earned Discretionary Annual Bonus will be paid not later than March 15 of the year following the year in which your right to such Discretionary Annual Bonus became vested. 

You will be granted a stock option to purchase 1,240,000 shares of the Company’s Common Stock pursuant to the terms set forth in the Company’s 2012
Equity Incentive Plan (the “Plan”) and the applicable stock option agreement and other documents thereunder. The exercise price of your stock option will be equal to the fair market value of the Common Stock on the date of grant as
determined by the Board. Provided that your employment with the Company continues through each of the following dates, (a) with respect to 414,000 of the shares subject to your stock option, 25% of such shares shall vest on February 7,
2012, and the remaining 75% of such shares shall vest in equal monthly installments thereafter over the subsequent three years, and (b) with respect to 826,000 of the shares subject to your stock option, 14% of such shares shall vest on
June 19, 2013, and the remaining 86% of such shares shall vest in equal monthly installments thereafter over the subsequent three years. You will be provided with a copy of the Plan and your stock option agreement following approval of the
grant. Such stock option agreement will provide, among other things, that upon an Asset Transfer or Acquisition (each as defined in the Company’s Amended and Restated Certificate of Incorporation) that is consummated while you are employed by
the Company 

  
 12531 High Bluff
Drive, Suite 110, San Diego, CA 92130. (858) 461-0694 
 www.lumenapharma.com 








 



 
  
 
(or within 90 days after your employment with the Company is involuntarily terminated without Cause (as defined in the Plan)), the vesting of the shares subject to your stock option will be
accelerated in full. 
 In addition, the Company agrees that as of the date hereof, the 138,000 restricted shares of Common Stock of the Company issued to
you pursuant to that certain Founder Stock Repurchase Agreement (the “Repurchase Agreement”), dated February 7, 2011, shall vest in full and thereby be released from the Company’s Purchase Option (as defined in the Repurchase
Agreement). 
 In the event your employment with the Company is involuntarily terminated without Cause, you will be entitled to receive a one-time lump sum
payment in an amount equal to four months of your Base Salary in effect at the time of termination, subject to payroll deductions and all required withholdings. The foregoing severance payment will be paid within 90 days of your termination of
employment, contingent upon your furnishing to the Company an executed release and waiver of claims in a form acceptable to the Company (the “Release and Waiver”) within the time frame set forth therein, but in no event later than 45 days
following the date of termination of your employment with the Company, and permitting the Release and Waiver to become effective in accordance with its terms (such latest permitted date on which the Release and Waiver may become effective, the
“Release Deadline”). Notwithstanding the foregoing, the severance payment will be paid to you not later than March 15 of the year following the year in which your termination of employment occurred. 

The following provisions apply to the extent the severance benefits provided in this Agreement are subject to Section 409A of the Internal Revenue Code
of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively “Section 409A”). Severance benefits will not commence until you have a “separation from
service” for purposes of Section 409A. Each installment of severance benefits is a separate “payment” for purposes of Treas. Reg. Section 1.409A-2(b)(2)(i), and the severance benefits are intended to satisfy the exemptions
from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), as applicable. However, if such exemptions are not available and you are, upon separation from service, a
“specified employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A, the timing of the severance benefits payments will be delayed until the
earlier of (a) six months and one day after your separation from service or (b) your death. If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release and Waiver could
become effective in the calendar year following the calendar year in which you separate from service, the Release and Waiver will not be deemed effective any earlier than the Release Deadline. The severance benefits are intended to qualify for an
exemption from application of Section 409A or to comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities in this Agreement will be interpreted accordingly.

 In the event that the severance and other benefits provided for in this Agreement or otherwise payable to you (a) constitute “parachute
payments” within the meaning of Section 280G of the Code, and (b) would be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then your benefits under this Agreement will be either
(x) delivered in full, or (y) delivered as to such lesser extent which would result in no portion of such benefits being subject to the Excise Tax (the “Adjusted Amount”), whichever of the foregoing amounts, taking into account
the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by you on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under
Section 4999 of the Code. Unless you and the Company otherwise agree in writing, any determination required under this paragraph will be made in writing by a mutually agreed independent public accounting firm or other independent third party
(the “Accountants”), whose determination will be conclusive and binding upon you and the Company for all purposes. The Company will bear all costs the Accountants may incur in connection with any calculations contemplated by this
paragraph. 

  
 12531 High Bluff
Drive, Suite 110, San Diego, CA 92130. (858) 461-0694 
 www.lumenapharma.com 








 



 
  
 As a Company employee, you will be expected to
abide by Company policies and procedures, and when it is implemented, acknowledge in writing that you have read and will comply with the Company’s Employee Handbook. 

In your work for the Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or
other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in
the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises or use in your work for the Company any unpublished documents or property
belonging to any former employer or third party that you are not authorized to use and disclose. 
 Your employment relationship is at will. You may
terminate your employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without Cause or advance notice. Your employment at-will
status can only be modified in a written agreement signed by you and by an authorized representative of the Company (which must be approved by the Board). 

This Agreement, along with your existing Employee Proprietary Information and Inventions Agreement dated February 7, 2011, form the complete and
exclusive statement of your employment relationship with the Company. The terms in this Agreement supersede any other agreements or promises made to you by anyone, whether oral or written, including without limitation the Prior Offer Letter. This
Agreement cannot be changed except in a written agreement signed by you and an authorized representative of the Company (which must be approved by the Board). 

The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California as applied to agreements
entered into and performed within California solely by residents of that state. 
 We look forward to your favorable reply and to a productive and enjoyable
work relationship. 
  

	
	Sincerely,
	
	 /s/ John McKearn

	John McKearn
	Chairman of the Board
	Lumena Pharmaceuticals. Inc.

  

					
	Accepted:	 		 	
			
	 /s/ Michael Grey
	 		 	 December 17, 2012

			
	Michael Grey	 		 	Date


  
 12531 High Bluff
Drive, Suite 110, San Diego, CA 92130. (858) 461-0694 
 www.lumenapharma.com 








 



 
  
 EXHIBIT A

 PERMITTED AFFILIATIONS 
 BioMarin
Pharmaceutical Inc.: Board Member 
 Horizon Pharma, Inc.: Board Member and Lead Independent Director 

Pappas Ventures: Venture Partner 
 Selventa, Inc.: Board Member

 Chimerix, Inc.: Board Observer 
 Achillion Pharmaceuticals,
Inc.: Consultant 

  
 12531 High Bluff
Drive, Suite 110, San Diego, CA 92130. (858) 461-0694 
 www.lumenapharma.com